Glucose metabolic reprogramming in autoimmune diseases

Autoimmune diseases are conditions in which the immune system mistakenly targets and damages healthy tissue in the body. In recent decades, the incidence of autoimmune diseases has increased, resulting in a significant disease burden. The current autoimmune therapies focus on targeting inflammation...

Full description

Saved in:
Bibliographic Details
Published in:Animal cells and systems 2023, 27(1), , pp.149-158
Main Authors: Jeong, Hoim, Lee, Beomgu, Han, Seung Jin, Sohn, Dong Hyun
Format: Article
Language:English
Subjects:
Autoimmune diseases
Chronic conditions
Diabetes
Diabetes mellitus (insulin dependent)
Disease
Energy
Enzymes
Glucose
Glucose metabolic reprogramming
glucose transporter
glycolysis
Immune system
Immunology
Immunosuppression
Lupus
Lymphocytes
Metabolic pathways
Metabolism
Metabolites
metformin
Multiple sclerosis
Oxidative stress
Phosphorylation
Review
Rheumatoid arthritis
Systemic lupus erythematosus
Systemic sclerosis
생물학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c598t-83baab3e1fe5adf924d29c9ee9becfe58ed2f4b3ed4ba9eebe7c6c736a7b17923
cites cdi_FETCH-LOGICAL-c598t-83baab3e1fe5adf924d29c9ee9becfe58ed2f4b3ed4ba9eebe7c6c736a7b17923
container_end_page 158
container_issue 1
container_start_page 149
container_title Animal cells and systems
container_volume 27
creator Jeong, Hoim
Lee, Beomgu
Han, Seung Jin
Sohn, Dong Hyun
description Autoimmune diseases are conditions in which the immune system mistakenly targets and damages healthy tissue in the body. In recent decades, the incidence of autoimmune diseases has increased, resulting in a significant disease burden. The current autoimmune therapies focus on targeting inflammation or inducing immunosuppression rather than addressing the underlying cause of the diseases. The activity of metabolic pathways is elevated in autoimmune diseases, and metabolic changes are increasingly recognized as important pathogenic processes underlying these. Therefore, metabolically targeted therapies may represent an important strategy for treating autoimmune diseases. This review provides a comprehensive overview of the evidence surrounding glucose metabolic reprogramming and its potential applications in drug discovery and development for autoimmune diseases, such as type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.
doi_str_mv 10.1080/19768354.2023.2234986
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_37465289</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_663a9585e1854983955818f82a010275</doaj_id><sourcerecordid>2839740427</sourcerecordid><originalsourceid>FETCH-LOGICAL-c598t-83baab3e1fe5adf924d29c9ee9becfe58ed2f4b3ed4ba9eebe7c6c736a7b17923</originalsourceid><addsrcrecordid>eNp9kk9v1DAQxSMEokvhI4BW4oIq7eL_sU-0qkpZqRISKmdr4kwWb5N4sRNQvz3OZltRDpxGGv_mzfPoFcVbStaUaPKRmlJpLsWaEcbXjHFhtHpWLBiVdMWEls-LxcSsJuikeJXSjhDFiDYvixNeCiWZNotCXbejCwmXHQ5Qhda7ZcR9DNsIXef77dL3SxiH4Ltu7HFZ-4SQML0uXjTQJnxzrKfF989Xt5dfVjdfrzeXFzcrJ40e8u4KoOJIG5RQN4aJmhlnEE2FLvc01qwRGahFBbldYemUK7mCsqKlYfy0OJt1-9jYO-dtAH-o22Dvor34druxlHAhiJIZ3sxwHWBn99F3EO8PE4dGiFsLcfCuRasUByO1RKplPhw3UmqqG82AUMLKSevTrLUfqw5rh_0QoX0i-vSl9z-yqV-TG0mF5Fnhw1Ehhp8jpsF2PjlsW-gxjMmyvLUURLAyo-__QXdhjH0-rGWG8FIpLadbyJlyMaQUsXl0Q4mdMmEfMmGnTNhjJvLcu7-_8jj1EIIMnM-A75sQO_gdYlvbAe7bEJsIvfPJ8v_v-AMeHsVN</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2903766852</pqid></control><display><type>article</type><title>Glucose metabolic reprogramming in autoimmune diseases</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><creator>Jeong, Hoim ; Lee, Beomgu ; Han, Seung Jin ; Sohn, Dong Hyun</creator><creatorcontrib>Jeong, Hoim ; Lee, Beomgu ; Han, Seung Jin ; Sohn, Dong Hyun</creatorcontrib><description>Autoimmune diseases are conditions in which the immune system mistakenly targets and damages healthy tissue in the body. In recent decades, the incidence of autoimmune diseases has increased, resulting in a significant disease burden. The current autoimmune therapies focus on targeting inflammation or inducing immunosuppression rather than addressing the underlying cause of the diseases. The activity of metabolic pathways is elevated in autoimmune diseases, and metabolic changes are increasingly recognized as important pathogenic processes underlying these. Therefore, metabolically targeted therapies may represent an important strategy for treating autoimmune diseases. This review provides a comprehensive overview of the evidence surrounding glucose metabolic reprogramming and its potential applications in drug discovery and development for autoimmune diseases, such as type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.</description><identifier>ISSN: 1976-8354</identifier><identifier>EISSN: 2151-2485</identifier><identifier>DOI: 10.1080/19768354.2023.2234986</identifier><identifier>PMID: 37465289</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Autoimmune diseases ; Chronic conditions ; Diabetes ; Diabetes mellitus (insulin dependent) ; Disease ; Energy ; Enzymes ; Glucose ; Glucose metabolic reprogramming ; glucose transporter ; glycolysis ; Immune system ; Immunology ; Immunosuppression ; Lupus ; Lymphocytes ; Metabolic pathways ; Metabolism ; Metabolites ; metformin ; Multiple sclerosis ; Oxidative stress ; Phosphorylation ; Review ; Rheumatoid arthritis ; Systemic lupus erythematosus ; Systemic sclerosis ; 생물학</subject><ispartof>Animal Cells and Systems, 2023, 27(1), , pp.149-158</ispartof><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group 2023</rights><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</rights><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group 2023 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c598t-83baab3e1fe5adf924d29c9ee9becfe58ed2f4b3ed4ba9eebe7c6c736a7b17923</citedby><cites>FETCH-LOGICAL-c598t-83baab3e1fe5adf924d29c9ee9becfe58ed2f4b3ed4ba9eebe7c6c736a7b17923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351453/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2903766852?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27502,27924,27925,37012,37013,44590,53791,53793,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37465289$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003030881$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Jeong, Hoim</creatorcontrib><creatorcontrib>Lee, Beomgu</creatorcontrib><creatorcontrib>Han, Seung Jin</creatorcontrib><creatorcontrib>Sohn, Dong Hyun</creatorcontrib><title>Glucose metabolic reprogramming in autoimmune diseases</title><title>Animal cells and systems</title><addtitle>Anim Cells Syst (Seoul)</addtitle><description>Autoimmune diseases are conditions in which the immune system mistakenly targets and damages healthy tissue in the body. In recent decades, the incidence of autoimmune diseases has increased, resulting in a significant disease burden. The current autoimmune therapies focus on targeting inflammation or inducing immunosuppression rather than addressing the underlying cause of the diseases. The activity of metabolic pathways is elevated in autoimmune diseases, and metabolic changes are increasingly recognized as important pathogenic processes underlying these. Therefore, metabolically targeted therapies may represent an important strategy for treating autoimmune diseases. This review provides a comprehensive overview of the evidence surrounding glucose metabolic reprogramming and its potential applications in drug discovery and development for autoimmune diseases, such as type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.</description><subject>Autoimmune diseases</subject><subject>Chronic conditions</subject><subject>Diabetes</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Disease</subject><subject>Energy</subject><subject>Enzymes</subject><subject>Glucose</subject><subject>Glucose metabolic reprogramming</subject><subject>glucose transporter</subject><subject>glycolysis</subject><subject>Immune system</subject><subject>Immunology</subject><subject>Immunosuppression</subject><subject>Lupus</subject><subject>Lymphocytes</subject><subject>Metabolic pathways</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>metformin</subject><subject>Multiple sclerosis</subject><subject>Oxidative stress</subject><subject>Phosphorylation</subject><subject>Review</subject><subject>Rheumatoid arthritis</subject><subject>Systemic lupus erythematosus</subject><subject>Systemic sclerosis</subject><subject>생물학</subject><issn>1976-8354</issn><issn>2151-2485</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk9v1DAQxSMEokvhI4BW4oIq7eL_sU-0qkpZqRISKmdr4kwWb5N4sRNQvz3OZltRDpxGGv_mzfPoFcVbStaUaPKRmlJpLsWaEcbXjHFhtHpWLBiVdMWEls-LxcSsJuikeJXSjhDFiDYvixNeCiWZNotCXbejCwmXHQ5Qhda7ZcR9DNsIXef77dL3SxiH4Ltu7HFZ-4SQML0uXjTQJnxzrKfF989Xt5dfVjdfrzeXFzcrJ40e8u4KoOJIG5RQN4aJmhlnEE2FLvc01qwRGahFBbldYemUK7mCsqKlYfy0OJt1-9jYO-dtAH-o22Dvor34druxlHAhiJIZ3sxwHWBn99F3EO8PE4dGiFsLcfCuRasUByO1RKplPhw3UmqqG82AUMLKSevTrLUfqw5rh_0QoX0i-vSl9z-yqV-TG0mF5Fnhw1Ehhp8jpsF2PjlsW-gxjMmyvLUURLAyo-__QXdhjH0-rGWG8FIpLadbyJlyMaQUsXl0Q4mdMmEfMmGnTNhjJvLcu7-_8jj1EIIMnM-A75sQO_gdYlvbAe7bEJsIvfPJ8v_v-AMeHsVN</recordid><startdate>20231211</startdate><enddate>20231211</enddate><creator>Jeong, Hoim</creator><creator>Lee, Beomgu</creator><creator>Han, Seung Jin</creator><creator>Sohn, Dong Hyun</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><general>Taylor &amp; Francis Group</general><general>한국통합생물학회</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7SN</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><scope>ACYCR</scope></search><sort><creationdate>20231211</creationdate><title>Glucose metabolic reprogramming in autoimmune diseases</title><author>Jeong, Hoim ; Lee, Beomgu ; Han, Seung Jin ; Sohn, Dong Hyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c598t-83baab3e1fe5adf924d29c9ee9becfe58ed2f4b3ed4ba9eebe7c6c736a7b17923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Autoimmune diseases</topic><topic>Chronic conditions</topic><topic>Diabetes</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Disease</topic><topic>Energy</topic><topic>Enzymes</topic><topic>Glucose</topic><topic>Glucose metabolic reprogramming</topic><topic>glucose transporter</topic><topic>glycolysis</topic><topic>Immune system</topic><topic>Immunology</topic><topic>Immunosuppression</topic><topic>Lupus</topic><topic>Lymphocytes</topic><topic>Metabolic pathways</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>metformin</topic><topic>Multiple sclerosis</topic><topic>Oxidative stress</topic><topic>Phosphorylation</topic><topic>Review</topic><topic>Rheumatoid arthritis</topic><topic>Systemic lupus erythematosus</topic><topic>Systemic sclerosis</topic><topic>생물학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jeong, Hoim</creatorcontrib><creatorcontrib>Lee, Beomgu</creatorcontrib><creatorcontrib>Han, Seung Jin</creatorcontrib><creatorcontrib>Sohn, Dong Hyun</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Ecology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>Korean Citation Index</collection><jtitle>Animal cells and systems</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jeong, Hoim</au><au>Lee, Beomgu</au><au>Han, Seung Jin</au><au>Sohn, Dong Hyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glucose metabolic reprogramming in autoimmune diseases</atitle><jtitle>Animal cells and systems</jtitle><addtitle>Anim Cells Syst (Seoul)</addtitle><date>2023-12-11</date><risdate>2023</risdate><volume>27</volume><issue>1</issue><spage>149</spage><epage>158</epage><pages>149-158</pages><issn>1976-8354</issn><eissn>2151-2485</eissn><abstract>Autoimmune diseases are conditions in which the immune system mistakenly targets and damages healthy tissue in the body. In recent decades, the incidence of autoimmune diseases has increased, resulting in a significant disease burden. The current autoimmune therapies focus on targeting inflammation or inducing immunosuppression rather than addressing the underlying cause of the diseases. The activity of metabolic pathways is elevated in autoimmune diseases, and metabolic changes are increasingly recognized as important pathogenic processes underlying these. Therefore, metabolically targeted therapies may represent an important strategy for treating autoimmune diseases. This review provides a comprehensive overview of the evidence surrounding glucose metabolic reprogramming and its potential applications in drug discovery and development for autoimmune diseases, such as type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>37465289</pmid><doi>10.1080/19768354.2023.2234986</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1976-8354
ispartof Animal Cells and Systems, 2023, 27(1), , pp.149-158
issn 1976-8354
2151-2485
language eng
recordid cdi_pubmed_primary_37465289
source Open Access: PubMed Central; Taylor & Francis Open Access; Publicly Available Content Database
subjects Autoimmune diseases
Chronic conditions
Diabetes
Diabetes mellitus (insulin dependent)
Disease
Energy
Enzymes
Glucose
Glucose metabolic reprogramming
glucose transporter
glycolysis
Immune system
Immunology
Immunosuppression
Lupus
Lymphocytes
Metabolic pathways
Metabolism
Metabolites
metformin
Multiple sclerosis
Oxidative stress
Phosphorylation
Review
Rheumatoid arthritis
Systemic lupus erythematosus
Systemic sclerosis
생물학
title Glucose metabolic reprogramming in autoimmune diseases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A39%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glucose%20metabolic%20reprogramming%20in%20autoimmune%20diseases&rft.jtitle=Animal%20cells%20and%20systems&rft.au=Jeong,%20Hoim&rft.date=2023-12-11&rft.volume=27&rft.issue=1&rft.spage=149&rft.epage=158&rft.pages=149-158&rft.issn=1976-8354&rft.eissn=2151-2485&rft_id=info:doi/10.1080/19768354.2023.2234986&rft_dat=%3Cproquest_pubme%3E2839740427%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c598t-83baab3e1fe5adf924d29c9ee9becfe58ed2f4b3ed4ba9eebe7c6c736a7b17923%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2903766852&rft_id=info:pmid/37465289&rfr_iscdi=true